Scinai Immunotherapeutics
SCNI
9 hedge funds and large institutions have $54.7K invested in Scinai Immunotherapeutics in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
25% less funds holding
Funds holding: 12 → 9 (-3)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
74% less capital invested
Capital invested by funds: $213K → $54.7K (-$158K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.96K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$415 |
| 3 |
APC
Aspire Private Capital
Cornelius,
North Carolina
|
+$66 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$63.2K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$31.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.31K |
| 4 |
Millennium Management
New York
|
-$5.48K |
| 5 |
Morgan Stanley
New York
|
-$12 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $49.6K | -$31.1K | -7,486 | -30% |
|
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $3.24K | +$1.96K | +473 | +71% |
|
|
3
Morgan Stanley
New York
| $709 | -$12 | -3 | -1% |
|
4
UBS Group
Zurich,
Switzerland
| $586 | -$4 | -1 | -0.5% |
|
|
5
Bank of America
Charlotte,
North Carolina
| $278 | +$415 | +100 | New |
|
6
Credit Agricole
Montrouge Cedex,
France
| $117 | – | – | – |
|
|
APC
7
Aspire Private Capital
Cornelius,
North Carolina
| $89 | +$66 | +16 | +100% |
|
|
MSG
8
Main Street Group
Glen Allen,
Virginia
| $59 | – | – | – |
|
|
GRP
9
Global Retirement Partners
San Rafael,
California
| $14 | – | – | – |
|
|
AC
10
Armistice Capital
New York
| – | -$63.2K | -12,179 | Closed |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$6.31K | -1,221 | Closed |
|
|
12
Millennium Management
New York
| – | -$5.48K | -1,061 | Closed |
|
13
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$4 | -1 | Closed |
|
SCNI Hedge Fund Activity: Q2 2024 in Review
9 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2024, worth a combined $54.7K — down 74% from $213K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SCNI and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was RhumbLine Advisers, adding an estimated $1.96K. The largest seller was Armistice Capital, exiting entirely with an estimated $63.2K sold.
- 9 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2024, down from 12 in Q1 2024.
- Funds reported $54.7K of Scinai Immunotherapeutics stock for Q2 2024, down 74% quarter-over-quarter.
- 1 fund opened new Scinai Immunotherapeutics positions in Q2 2024 and 4 closed out, a net change of -3 holders.
- The largest Scinai Immunotherapeutics buyer in Q2 2024 was RhumbLine Advisers, an estimated $1.96K added.
- The largest Scinai Immunotherapeutics seller in Q2 2024 was Armistice Capital, an estimated $63.2K sold.
Based on aggregated 13F filings for Q2 2024.